Linganisha mbinu
Pitia mbinu ulizochagua bega kwa bega; safu zinazotofautiana zinaangaziwa.
| Chombo cha Tathmini ya Mtazamo kuhusu Dawa (DAI)× | Kiwalajishaji cha Kuridhika na Matibabu kwa Ajili ya Dawa (TSQM)× | |
|---|---|---|
| Nyanja | Famakolojia | Famakolojia |
| Familia | Process / pipeline | Process / pipeline |
| Mwaka wa asili≠ | 1983 | 2004 |
| Mwanzilishi≠ | Thomas P. Hogan, Ahmed G. Awad, and Robert Eastwood | Mary Jo Atkinson and colleagues |
| Aina | Self-report | Self-report |
| Chanzo asilia≠ | Hogan, T. P., Awad, A. G., & Eastwood, R. (1983). A self-report scale predictive of drug compliance in schizophrenics: Reliability and discriminative validity. Psychological Medicine, 13(1), 177-183. DOI ↗ | Atkinson, M. J., Sinha, A., Hass, S. L., Colman, S. S., Kumar, R. N., Berman, B. M., & Wolpert, B. (2004). Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel of chronically ill individuals. Health and Quality of Life Outcomes, 2(1), 12. DOI ↗ |
| Majina mbadala≠ | DAI, DAI-10, DAI-30 | TSQM |
| Zinazohusiana | 4 | 4 |
| Muhtasari≠ | The Drug Attitude Inventory (DAI) is a brief self-report measure developed by Hogan, Awad, and Eastwood in 1983 to assess attitudes toward medication and predicted medication compliance in schizophrenia and other psychiatric conditions. The original 30-item version (DAI-30) and the widely used 10-item short form (DAI-10) capture patients' subjective experience of medication benefit, side effects, and overall willingness to take medication as a predictor of adherence. The DAI is particularly valuable in psychiatric care, where attitudes toward antipsychotic and antidepressant medications strongly predict adherence and clinical outcomes. | The Treatment Satisfaction Questionnaire for Medication (TSQM) is a 14-item generic measure developed by Atkinson and colleagues in 2004 to assess patient satisfaction with medication across diverse therapeutic areas and disease conditions. It measures four key dimensions—Effectiveness, Side Effects, Convenience, and Global Satisfaction—with standardized 0–100 scoring, making it suitable for cross-disease comparison and health economic evaluation. The TSQM has become a standard outcome in pharmaceutical research, clinical trials, and real-world medication effectiveness studies. |
| ScholarGateSeti ya data ↗ |
|
|